Aspen expands China interests as Sandoz deal gets green light
The pharmaceutical group has received the necessary regulatory approvals from Chinese authorities to conclude two linked transactions
04 April 2024 - 15:49
Pharmaceuticals and biotechnology major Aspen has finalised the acquisition of Sandoz China, gaining a bigger foothold into the world’s second-largest pharmaceutical market as it steams ahead with its diversification strategy.
In a statement on Thursday, Africa’s biggest pharmaceutical manufacturer said that it had received all the necessary regulatory approvals to conclude its acquisition of Swiss drug maker Sandoz’s Chinese subsidiary for up to €92.6m (R1.9bn)...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.